128 related articles for article (PubMed ID: 18089826)
1. Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand.
Gregory MS; Saff RR; Marshak-Rothstein A; Ksander BR
Cancer Res; 2007 Dec; 67(24):11951-8. PubMed ID: 18089826
[TBL] [Abstract][Full Text] [Related]
2. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
[TBL] [Abstract][Full Text] [Related]
3. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
[TBL] [Abstract][Full Text] [Related]
4. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.
Dupont PJ; Warrens AN
Immunology; 2007 Jan; 120(1):133-9. PubMed ID: 17233740
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
[TBL] [Abstract][Full Text] [Related]
6. Soluble Fas ligand blocks destructive corneal inflammation in mouse models of corneal epithelial debridement and LPS induced keratitis.
Gregory-Ksander M; Perez VL; Marshak-Rothstein A; Ksander BR
Exp Eye Res; 2019 Feb; 179():47-54. PubMed ID: 30365944
[TBL] [Abstract][Full Text] [Related]
7. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
Wada A; Tada Y; Kawamura K; Takiguchi Y; Tatsumi K; Kuriyama T; Takenouchi T; O-Wang J; Tagawa M
Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
[TBL] [Abstract][Full Text] [Related]
8. Presence of membrane and soluble forms of Fas ligand and of matrilysin (MMP-7) activity in normal and abnormal human semen.
Riccioli A; Dal Secco V; De Cesaris P; Starace D; Gandini L; Lenzi A; Dondero F; Padula F; Filippini A; Ziparo E
Hum Reprod; 2005 Oct; 20(10):2814-20. PubMed ID: 15979995
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of apoptotic Fas ligand-expressing tumors decreased antitumor responses by enhanced production of immunosuppressive cytokines.
Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2005; 25(1A):299-303. PubMed ID: 15816551
[TBL] [Abstract][Full Text] [Related]
10. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma.
Koshkina NV; Khanna C; Mendoza A; Guan H; DeLauter L; Kleinerman ES
Mol Cancer Res; 2007 Oct; 5(10):991-9. PubMed ID: 17951400
[TBL] [Abstract][Full Text] [Related]
11. The FasLane to ocular pathology-metalloproteinase cleavage of membrane-bound FasL determines FasL function.
Gregory-Ksander M; Marshak-Rothstein A
J Leukoc Biol; 2021 Nov; 110(5):965-977. PubMed ID: 33565149
[TBL] [Abstract][Full Text] [Related]
12. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
Modiano JF; Sun J; Lang J; Vacano G; Patterson D; Chan D; Franzusoff A; Gianani R; Meech SJ; Duke R; Bellgrau D
Clin Immunol; 2004 Jul; 112(1):54-65. PubMed ID: 15207782
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of Soluble Fas Ligand following Adeno-Associated Virus Gene Therapy Prevents Retinal Ganglion Cell Death in Chronic and Acute Murine Models of Glaucoma.
Krishnan A; Fei F; Jones A; Busto P; Marshak-Rothstein A; Ksander BR; Gregory-Ksander M
J Immunol; 2016 Dec; 197(12):4626-4638. PubMed ID: 27849168
[TBL] [Abstract][Full Text] [Related]
14. Membrane-bound and soluble Fas ligands have opposite functions in photoreceptor cell death following separation from the retinal pigment epithelium.
Matsumoto H; Murakami Y; Kataoka K; Notomi S; Mantopoulos D; Trichonas G; Miller JW; Gregory MS; Ksander BR; Marshak-Rothstein A; Vavvas DG
Cell Death Dis; 2015 Nov; 6(11):e1986. PubMed ID: 26583327
[TBL] [Abstract][Full Text] [Related]
15. Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model.
Fingleton B; Carter KJ; Matrisian LM
Cancer Res; 2007 May; 67(10):4800-6. PubMed ID: 17510409
[TBL] [Abstract][Full Text] [Related]
16. Expression of FasL by tumor cells does not abrogate anti-tumor CTL function.
Lee SH; Bar-Haim E; Goldberger O; Reich-Zeliger S; Vadai E; Tzehoval E; Eisenbach L
Immunol Lett; 2004 Feb; 91(2-3):119-26. PubMed ID: 15019279
[TBL] [Abstract][Full Text] [Related]
17. Role of Fas ligand in ocular tissue.
Sano Y; Sotozono C
Cornea; 2002 Mar; 21(2 Suppl 1):S30-2. PubMed ID: 11995807
[TBL] [Abstract][Full Text] [Related]
18. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
19. In vivo controlling of cellular response to pig islet xenografts by adenovirus-mediated expression of either membrane-bound human FasL or human decoy Fas.
Kawamoto K; Tanemura M; Deguchi T; Machida T; Nishida T; Sawa Y; Doki Y; Mori M; Ito T
Transplant Proc; 2009; 41(1):331-3. PubMed ID: 19249549
[TBL] [Abstract][Full Text] [Related]
20. Non-cleavable mutant Fas ligand transfection of donor cornea abrogates ocular immune privilege.
Sano Y; Yamada J; Ishino Y; Adachi W; Kawasaki S; Suzuki T; Kinoshita S; Okuyama T; Azuma N
Exp Eye Res; 2002 Oct; 75(4):475-83. PubMed ID: 12387794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
